Objective To evaluate the safety and effectiveness of early atorvastatin sequential therapy in coronary heart disease (CHD) patients after percutaneous coronary intervention (PCI). Methods A total of 170 CHD patients ready to receive PCI were randomly divided into sequential dose group (group A: atorvastatin 80mg as loading dose, then 40mg/d for 1 month and 20mg/d subsequently, n=85) and ordinary dose group (group B: atorvastatin 20mg/d, n=85).Laboratory records, such as blood lipid, hepatic function, renal function, creatine kinase (CK), hypersensitive Creactive protein (CRP) were observed at different time points including 1 week, 1 month, 3 months and 6 months. Main adverse cardiac events and adverse effects were also analyzed. Results Compared with baseline, the level of low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) was significantly decreased at each time points in both two groups(P＜0.05). The decreasing degree of LDL-C and TC level at 1 week had significant differences between two groups(LDL-C:31.2% vs 12.5%;TC:29.2% vs 13.1%;P＜0.05); meanwhile, the decreasing degree was keeping enlarged at 1 month between two groups(LDL-C: 43.0% vs 17.6%;TC: 41.3% vs 22.3%;P＜0.05). The change in LDL-C and TC level was not significantly different between the two groups at 3 and 6 months (P＞0.05). The rate that LDL-C met predefined standard in group A was significantly higher than that in group B at 1 week, 1 month and 3 months respectively. The hsCRP level was significantly decreased in both groups, which was more significant in group A than in group B at 1 week and 1 month[group A: (8.17±5.69)mg/L at pretreatment, (4.23±2.43)mg/L at 1 week, and (1.96±0.77)mg/L at 1 month respectively; groupB: (7.75±4.31)mg/L at pretreatment, (4.87±2.70)mg/L at 1 week, and (3.21±1.27)mg/L at 1 month respectively; P＜0.05]. Incidence of main adverse cardiac events was significantly lower in group A than in group B at 6 months (5.9% vs15.3%, P＜0.05), which further decreased by 9.4% in group A. The adverse effects were very trivial and had no significant difference between two groups (P＞0.05). Conclusion The atorvastatin sequential therapy early used in CHD patients after PCI is superior to ordinary atorvastatin therapy in efficacy, which shows better clinical prognosis without increase of adverse effects.